EsoMedical Completes Nearly $100 Million Series C Financing to Accelerate Industrialization and Scale-up

VCBeat learned that MitrAssist Lifesciences (referred to as "MitrAssist"), a global leader in innovative cardiovascular medical devices, announced today the completion of its nearly US$100 million Series C financing. This round of financing was led by Centurium Capital and 6 Dimensions Capital, with co-investments from Shanghai Jiading Industrial Zone Development Group, Shanghai Jiajia Group, Hefei Haiheng Capital, Hefei Industrial Investment, Hefei Binhu Sci-Tech Innovation Investment, and Anyuan Capital.

The funds raised in this round will support the registration clinical trials and market access work for the company's globally leading transcatheter mitral valve replacement product and polymer-based transcatheter aortic valve replacement product (Polymer TAVR), and complete the pre-registration clinical research work for other polymer valve products in the pipeline; promote the market sales of non-invasive heart failure monitoring devices and coronary drug-coated balloons; continuously improve the product portfolio; expand the production capacity of existing products; drive the promotion and application of products both domestically and internationally, further accelerating industrialization and scaling.

Chairman of MitrAssist Lifesciences, Ms. Wang LiThe investment by top-tier investment institutions in MitrAssist Lifesciences demonstrates the market's high recognition and support for the company. MitrAssist Lifesciences Group will continue to adhere to its core values of "MitrAssist Lifesciences, guided by the heart, driven by global technology, and dedicated to healing hearts worldwide." By uniting efforts and forging ahead with determination, the company aims to become a leading cardiovascular platform company in China and even globally, making greater contributions to the development of the innovative medical device industry and regional progress.

Centurium CapitalMitrAssist Lifesciences stated: "As a leading cardiovascular device platform company, MitrAssist Lifesciences has been providing innovative products and solutions for the health of patients worldwide. We look forward to the company continuing to play a leading role in this field, delivering more products to clinical practice, and helping more patients achieve health and happiness. We hope that our continued investment can contribute to improving patients' lives and advancing the development of medical technology!"

Hefei HaihengMitrAssist Lifesciences is one of the world's first companies to develop a transcatheter mitral valve replacement system and a leading provider of cardiovascular interventional product solutions globally. In the future, it will significantly address the pain points of structural heart patients in China. The transcatheter mitral valve replacement product is expected to fill a domestic gap in China. This round of financing for MitrAssist Lifesciences will accelerate the research, development, production, and commercialization of products such as non-invasive heart failure pulmonary fluid monitoring devices, drug-coated balloons, and structural heart products in Hefei.

MitrAssist Lifesciences, founded in 2017, is a globally leading innovative platform-based medical device enterprise in the cardiovascular field. Its products cover major areas such as structural heart, heart failure, and coronary artery disease. The company owns 153 authorized PCT patents worldwide. It has established R&D centers in China, Israel, and Germany, built a sales team in the United States, possesses a rich product pipeline, and has developed a distributor system in multiple countries.

The founding team of the group company consists of senior professionals who have been deeply engaged in the medical industry for many years, possessing disruptive technological innovation capabilities and outstanding international perspectives. Since its establishment, MitrAssist Lifesciences has always adhered to the philosophy of "MitrAssist Lifesciences, with heart as the guiding light, leveraging global technology to heal hearts worldwide," taking the strategic mission of achieving universal accessibility in cardiovascular medical diagnosis and treatment. Continuously innovating and striving to achieve "excellence where others exist, and uniqueness where others do not." The fully ultrasound-guided mitral valve interventional replacement product developed by MitrAssist Lifesciences is not only safe and reliable but also easy to use and convenient to promote. On July 6, 2022, the world's first polymer valve Polymer TAVR product independently developed by MitrAssist Lifesciences was successfully clinically implanted globally by a team led by Academician Ge Junbo at Zhongshan Hospital Affiliated with Fudan University in Shanghai, marking the entry of interventional treatment for valvular heart disease into the polymer new era. This project also won the highest award, the "Outstanding Award," in the 2022 Disruptive Technology Innovation Competition organized by the Ministry of Science and Technology. MitrAssist Lifesciences independently developed China’s first transapical mitral valve interventional replacement product, Mitrafix.^®Entered the special review of innovative medical devices by the National Medical Products Administration. ReDS™Pro, a non-invasive heart failure management device from MitrAssist Lifesciences, has been approved for marketing in China this year after being launched in the US, Europe, India, and Japan.